Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
      Google Scholar   
Citation:
J Clin Oncol vol 22 (6) 1025-33
Year:
2004
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
CA03927, CA11789, CA31946, CA31983, CA41287, CA47577, CA60138, CA77440  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
CALGB-9583
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Adenocarcinoma, Aged, Androgen Antagonists, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Humans, Hydrocortisone, Ketoconazole, Male, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms, Survival Analysis